Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

Trial Profile

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
    • 29 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Nov 2018.
    • 21 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top